ATE377000T1 - 5-ht1f agonisten - Google Patents
5-ht1f agonistenInfo
- Publication number
- ATE377000T1 ATE377000T1 AT00915719T AT00915719T ATE377000T1 AT E377000 T1 ATE377000 T1 AT E377000T1 AT 00915719 T AT00915719 T AT 00915719T AT 00915719 T AT00915719 T AT 00915719T AT E377000 T1 ATE377000 T1 AT E377000T1
- Authority
- AT
- Austria
- Prior art keywords
- ht1f agonists
- ht1f
- agonists
- mammal
- activating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11959699P | 1999-02-10 | 1999-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE377000T1 true ATE377000T1 (de) | 2007-11-15 |
Family
ID=22385241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00915719T ATE377000T1 (de) | 1999-02-10 | 2000-02-09 | 5-ht1f agonisten |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1153013B1 (de) |
| JP (1) | JP2002536434A (de) |
| KR (1) | KR20010102003A (de) |
| CN (1) | CN1149195C (de) |
| AT (1) | ATE377000T1 (de) |
| AU (1) | AU770098B2 (de) |
| BR (1) | BR0008112A (de) |
| CA (1) | CA2360164A1 (de) |
| DE (1) | DE60036924T2 (de) |
| ES (1) | ES2295017T3 (de) |
| WO (1) | WO2000047559A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040011447A (ko) * | 2000-12-22 | 2004-02-05 | 쉐링 코포레이션 | 피페리딘 ｍｃｈ 길항제 및 비만 치료에 있어서의 이의 용도 |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| CN1777584A (zh) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物 |
| UA82711C2 (en) * | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
| JP2007516266A (ja) | 2003-12-17 | 2007-06-21 | イーライ リリー アンド カンパニー | ５−ｈｔ１ｆアゴニストとしての置換（４−アミノシクロヘキセン−１−イル）フェニルおよび（４−アミノシクロヘキセン−１−イル）ピリジニル化合物 |
| US20080021034A1 (en) * | 2006-04-10 | 2008-01-24 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
| TW200914020A (en) * | 2007-08-28 | 2009-04-01 | Lilly Co Eli | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists |
| WO2011123654A1 (en) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists |
| WO2016027757A1 (ja) * | 2014-08-18 | 2016-02-25 | 国立大学法人大阪大学 | 新規２－アミノベンゾイル誘導体 |
| TWI829107B (zh) | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
| CN110981854B (zh) * | 2019-09-10 | 2023-03-28 | 南京三元阳普医药科技有限公司 | 2-氨基-6-(1-烷基哌啶-4-羰基)吡啶类化合物的合成方法 |
| CN111187252B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基氮杂螺庚烷衍生物及其用途 |
| CN111187251B (zh) * | 2019-11-22 | 2023-06-09 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| CN111004214B (zh) * | 2019-11-22 | 2021-06-08 | 广东东阳光药业有限公司 | 吡啶酰基哌啶衍生物及其用途 |
| CN110845402B (zh) * | 2019-11-22 | 2023-05-09 | 广东东阳光药业有限公司 | 吡啶亚甲基哌嗪衍生物及其用途 |
| WO2021097781A1 (zh) * | 2019-11-22 | 2021-05-27 | 广东东阳光药业有限公司 | 吡啶亚甲基哌啶衍生物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA944513B (en) * | 1993-06-23 | 1996-01-16 | Cambridge Neuroscience Inc | Sigma receptor ligands |
| CZ288897A3 (cs) * | 1995-03-20 | 1998-02-18 | Eli Lilly And Company | V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje |
| AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
-
2000
- 2000-02-09 KR KR1020017010048A patent/KR20010102003A/ko not_active Application Discontinuation
- 2000-02-09 WO PCT/US2000/002502 patent/WO2000047559A2/en active IP Right Grant
- 2000-02-09 BR BR0008112-4A patent/BR0008112A/pt not_active IP Right Cessation
- 2000-02-09 AT AT00915719T patent/ATE377000T1/de not_active IP Right Cessation
- 2000-02-09 AU AU36945/00A patent/AU770098B2/en not_active Ceased
- 2000-02-09 ES ES00915719T patent/ES2295017T3/es not_active Expired - Lifetime
- 2000-02-09 EP EP00915719A patent/EP1153013B1/de not_active Expired - Lifetime
- 2000-02-09 CA CA002360164A patent/CA2360164A1/en not_active Abandoned
- 2000-02-09 CN CNB008035768A patent/CN1149195C/zh not_active Expired - Fee Related
- 2000-02-09 DE DE60036924T patent/DE60036924T2/de not_active Expired - Fee Related
- 2000-02-09 JP JP2000598480A patent/JP2002536434A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU3694500A (en) | 2000-08-29 |
| EP1153013A2 (de) | 2001-11-14 |
| CN1149195C (zh) | 2004-05-12 |
| CN1340045A (zh) | 2002-03-13 |
| EP1153013B1 (de) | 2007-10-31 |
| DE60036924D1 (de) | 2007-12-13 |
| AU770098B2 (en) | 2004-02-12 |
| CA2360164A1 (en) | 2000-08-17 |
| WO2000047559A2 (en) | 2000-08-17 |
| BR0008112A (pt) | 2001-11-13 |
| JP2002536434A (ja) | 2002-10-29 |
| KR20010102003A (ko) | 2001-11-15 |
| ES2295017T3 (es) | 2008-04-16 |
| WO2000047559A3 (en) | 2000-11-30 |
| DE60036924T2 (de) | 2008-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69912279D1 (de) | 5-ht1f agonisten | |
| ATE377000T1 (de) | 5-ht1f agonisten | |
| WO2000006173A8 (en) | 5-ht1f agonists | |
| TR200302242T2 (tr) | Protein kinaz önleyicileri olarak pirolopirimidinler | |
| EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
| TR200201668T2 (tr) | Vla-4' e bağlı hücre bağlamasının peptidilsiz önleyicileri | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| DK0850221T3 (da) | Meta-guanidin-, urinstof-, thiourinstof- eller azacykliske aminobenzoesyrederivater som intergrinantagonister | |
| BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
| NO20003018L (no) | Triazinangiogenese-inhibitorer | |
| PE20011085A1 (es) | Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos | |
| MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
| NO985518L (no) | Morfinanderivater og medisinsk anvendelse derav | |
| UY26851A1 (es) | Derivados de la 4-fenilpiridina | |
| WO2000000490A3 (en) | 5-ht1f agonists | |
| TNSN04138A1 (fr) | Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique | |
| NO20014127L (no) | 5-HT1F agonister | |
| TNSN99146A1 (fr) | Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| BR0314714A (pt) | Compostos para o tratamento da doença de alzheimer | |
| ATE308513T1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| UY27570A1 (es) | Sal de ácido cítrico de un compuesto terapéutico y composiciones farmacéuticas que la contienen | |
| US6541495B1 (en) | Carboxylic acid derivatives as inhibitors of hyperproliferation diseases | |
| MXPA04000952A (es) | Sales de derivados de acido 1,2,3-4-tetrahidro-isoquinolin-2-carboxilico. | |
| BR0211127A (pt) | Utilização de um composto | |
| WO2017098514A1 (en) | Nupharidine compounds and derivatives thereof for the treatment of cysteine protease related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |